SiDMAP Founders to Provide Metabolomics Component of $5.6 Million
Center Grant from the NIH to Study Mechanisms of Action in Both
Inflammatory and Proliferative Diseases of the Pancreas
LOS ANGELES (Business Wire EON/PRWEB ) February 21, 2008 --
SiDMAP, LLC, announced today that its co-founders, Drs. Paul Lee and
Laszlo G. Boros, will provide the metabolic profiling component of the
research conducted by the UCLA Center for Excellence in Pancreatic
Disease, which recently received over $5.6 million from the NIH to study
various disease mechanisms in the pancreas. The UCLA Center for
Excellence in Pancreatic Disease is part of several grants recently
received by UCLA investigators to study pancreatic related illnesses
totaling $8,696,865.
“We are extremely proud of Drs. Boros and Lee
for their work in this area and for their recognition as investigators
with the unique skills and experience in the area of metabolic profiling
necessary to perform this important research,”
said Ms. Agi Hirshberg, President and Founder of SiDMAP. “The
multidisciplinary work to be performed by all the participating
investigators who received funding from the NIH, will hopefully yield
new insight into diseases of the pancreas and in particular, pancreatic
cancer and the discovery of more effective treatments and reliable tools
for earlier detection.”
“We are excited to join this collaborative
research effort and are pleased to be recognized by the NIH as the
participating metabolomics solution provider for this important project,”
Dr. Lee commented.
The SiDMAP platform will be used by Drs. Lee and Boros to provide
metabolic flux profiles in various models with the goal of understanding
the phytonutrient mechanism of action in both inflammatory and
proliferative diseases of the pancreas.
About SiDMAP
SiDMAP provides flux-based, metabolic profiling services to
pharmaceutical, biotech and research organizations seeking to enhance
their drug development processes, and develop further insights into a
drug’s mechanism of action and disease states.
SiDMAP’s unique tracer technology, exclusively
licensed from Los Angeles BioMedical Research Institute at Harbor
U.C.L.A Medical Center, measures metabolic pathway flux to gain unique
insights into cell function. A SiDMAP assay provides clients with an
accurate, dynamic metabolic analysis of a compound’s
biological impact in both in vitro and in vivo systems and
in humans for the development of clinical and pre-clinical biomarkers.
SiDMAP is headquartered in Los Angeles, California.
Post Comment:
Trackback URL: http://www.prweb.com/pingpr.php/Q3Jhcy1DcmFzLVN1bW0tQ3Jhcy1aZXRhLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
Share The News
Submit this press release easily to any of these major bookmarking and social media sites.